Features of the AVCJ May 12 2020 issue: Vietnam: Southeast Asia's enduring star? India: Regulators target Chinese investors Deals: RWDC on replacing single-use plastic Q&A: LTCV's Chris Tay talks...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.